What Senti Biosciences Holdings Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 2 | 6 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 177,265 | 274,263 |
| Net activity | −177,265 | −274,263 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Oct 21 | Withheld — tax / exercise cost · F | −19,953 | — | — | 54,890 |
| Lu Timothy K | CEO | Oct 21 | Withheld — tax / exercise cost · F | −157,312 | — | — | 482,271 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Mar 09 | Withheld — tax / exercise cost · F | −10,757 | — | — | 74,843 |
| Lu Timothy K | CEO | Mar 09 | Withheld — tax / exercise cost · F | −80,666 | — | — | 639,583 |
| Lu Timothy K | CEO | Feb 02 | Withheld — tax / exercise cost · F | −4,191 | — | — | 720,249 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Feb 02 | Withheld — tax / exercise cost · F | −1,384 | — | — | 85,600 |
| Celadon Partners Spv 24 | 10% owner | Mar 10 | Derivative Conversion · C | +9,777,000 | — | — | 9,777,000 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Mar 10 | Derivative Conversion · C | +33,000 | $2.25 | +$74.3K | 33,000 |
| Bayer Healthcare Llc | 10% owner | Mar 10 | Derivative Conversion · C | +2,222,000 | — | — | 2,809,848 |
| New Enterprise Associates 15, L.p. | 10% owner | Mar 10 | Derivative Conversion · C | +3,333,000 | — | — | 3,775,615 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Mar 07 | Grant / award · A | +78,363 | — | — | 86,984 |
| Lu Timothy K | CEO and Interim PFO and PAO | Mar 07 | Grant / award · A | +642,358 | — | — | 724,440 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Feb 06 | Open-market sale · S | −182 | $4.37 | −$795 | 8,621 |
| Lu Timothy K | CEO | Feb 06 | Open-market sale · S | −545 | $4.36 | −$2.38K | 82,082 |
| Rajangam Kanya | Pres. & Chief Med. & Dev. Off. | Feb 04 | Open-market sale · S | −1,297 | $4.07 | −$5.28K | 8,803 |
| Lu Timothy K | CEO | Feb 04 | Open-market sale · S | −3,922 | $4.07 | −$16K | 82,627 |
| Rajangam Kanya | Chief Medical & Devt. Officer | Feb 01 | Grant / award · A | +101,000 | — | — | 101,000 |
| Lu Timothy K | CEO and President | Feb 01 | Grant / award · A | +306,000 | — | — | 865,496 |
| Knobelman Deborah | Chief Financial Officer | Feb 01 | Grant / award · A | +101,000 | — | — | 131,000 |
| Knobelman Deborah | Chief Financial Officer | Oct 03 | Grant / award · A | +30,000 | — | — | 30,000 |
Loading...
